This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Biotricity Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biotricity.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili	25.8%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	05 Mar 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:QB00 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2025	14	N/A	N/A	N/A	1
3/31/2024	12	-15	-7	-7	N/A
12/31/2023	12	-15	-7	-7	N/A
9/30/2023	11	-17	-9	-9	N/A
6/30/2023	11	-18	-11	-11	N/A
3/31/2023	10	-20	-14	-14	N/A
12/31/2022	9	-21	-16	-16	N/A
9/30/2022	9	-23	-18	-18	N/A
6/30/2022	8	-29	-17	-17	N/A
3/31/2022	8	-30	-15	-15	N/A
12/31/2021	7	-30	-14	-14	N/A
9/30/2021	6	-27	-12	-12	N/A
6/30/2021	5	-19	-11	-11	N/A
3/31/2021	3	-16	-11	-11	N/A
12/31/2020	3	-16	-10	-10	N/A
9/30/2020	2	-14	-10	-10	N/A
6/30/2020	2	-13	-9	-9	N/A
3/31/2020	1	-11	-8	-8	N/A
12/31/2019	1	-8	-6	-6	N/A
9/30/2019	1	-8	-5	-5	N/A
6/30/2019	1	-8	-5	-5	N/A
3/31/2019	0	-9	-5	-5	N/A
12/31/2018	0	-10	-6	-6	N/A
9/30/2018	0	-9	-5	-5	N/A
6/30/2018	0	-9	-5	-5	N/A
3/31/2018	N/A	-9	-5	-5	N/A
12/31/2017	N/A	-8	N/A	-5	N/A
9/30/2017	N/A	-8	N/A	-5	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-8	N/A	-4	N/A
12/31/2016	N/A	-7	N/A	-2	N/A
9/30/2016	N/A	-6	N/A	-2	N/A
6/30/2016	N/A	-5	N/A	-2	N/A
3/31/2016	N/A	-5	N/A	-2	N/A
12/31/2015	N/A	-5	N/A	-2	N/A
9/30/2015	N/A	-4	N/A	-2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if QB00's forecast earnings growth is above the savings rate (0.8%).

Guadagni vs Mercato: Insufficient data to determine if QB00's earnings are forecast to grow faster than the German market

Guadagni ad alta crescita: Insufficient data to determine if QB00's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if QB00's revenue is forecast to grow faster than the German market.

Ricavi ad alta crescita: Insufficient data to determine if QB00's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if QB00's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Biotricity Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Less than half of directors are independent

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita